Dear current and prospective investors, In response to Australia's mental health crisis, Emyria Ltd is dedicated to providing advanced therapies and compassionate care. We are focused on improving patient outcomes in neuroscience and mental health through our clinical service delivery, real-world data, and drug development initiatives. Despite the challenging market conditions, our commitment to innovation and patient care remains steadfast. Our recent financial data reflects a decrease in revenue but a significant decrease in net loss, showcasing our continued efforts to optimize our operations. We are actively working on developing proprietary ultra-pure cannabinoid dose forms and advancing them towards registration, such as EMD-RX5. Additionally, our partnerships and advanced data platform operated by Palantir enable us to collect robust real-world data to enhance our care models and support therapy and drug development initiatives. We invite you to engage with us and ask any questions you may have regarding our recent initiatives and future plans. Our focus on addressing the growing global mental health challenge positions us uniquely in the market, with a clear growth strategy and major unmet needs to address. Thank you for your continued support and interest in Emyria Ltd. Best regards, [Management Team at Emyria]